Background A 2000 meta-analysis indicated no overall association between breast implants and risk of connective-tissue diseases (CTDs). However, a large retrospective cohort study we previously conducted suggested, instead, a small increased risk of CTDs. Because of limitations inherent to the retrospective cohort study design, we sought clarification by conducting a prospective cohort study of the association of breast implants with CTD risk.
Introduction
Cosmetic breast surgery has been performed for 4100 years, with the silicone breast implant introduced in 1962. 1 Today, one of the most common cosmetic surgical procedures is breast augmentation: more than 260 000 US women underwent this procedure in 2005, more than a doubling of the number doing so in 1998. 2 In the UK, breast augmentation rates increased by 275% between 2002 and 2008. 3 In the decades following the introduction of the silicone breast implant, several case reports and case series raised concerns about potential adverse health effects, particularly increased risks of connectivetissue diseases (CTDs), associated with such implants. [4] [5] [6] Although the interpretation of findings from these studies is difficult because there is no comparison group (women without silicone breast implants), the US Food and Drug Administration (FDA) in 1992 banned the use of silicone breast implants, except in clinical trials, citing inadequate data on their safety. 5 Following the ban, case-control and cohort studies were conducted over the next several years to investigate whether breast implants did indeed increase the risks of CTDs. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Overall, these studies indicated no increased risks of CTDs among women with breast implants, compared with non-implanted women. 1, [26] [27] [28] A meta-analysis of 13 studies published in 2000 estimated an adjusted summary rate ratio (RR) of 0.80 [95% confidence interval (CI) 0.62-1.04] for CTDs associated with breast implants. 26 For six studies that specifically examined silicone breast implants, the summary RR was 0.82 (95% CI 0.46-1.46). 26 These data led to the FDA lifting its ban in 2006, approving silicone-gel filled breast implants made by two companies, Allergan and Mentor. 29 Although the studies utilizing appropriate comparison groups indicated no increased risks of CTDs with breast implants when viewed in totality, not all individual studies supported this. In particular, the results from two large studies departed from the overall findings, reporting, instead, increased risks of CTDs with RRs ¼ 1.24 (95% CI 1.08-1.41) in a 1996 study 18 and 2.0 (95% CI 1.5-2.8) in a 2004 study. 13 The former finding was from a retrospective cohort study of almost 400 000 women conducted by our research group. Although this study is the largest study of breast implants and CTDs to date, its limitations included the retrospective assessment of breast implants (thus, recall of this may have been biased among women who went on to develop a CTD), lack of ascertainment of the type of breast implant (silicone vs non-silicone) and self-reported CTD. We therefore conducted a prospective cohort study to investigate the association of breast implants with risk of CTDs, utilizing eligible women from the same population as the 1996 study, but addressing the limitations of the previous study listed above.
Methods

Study subjects
Participants were from the 426 774 women comprising the eligible study population for our 1996 retrospective cohort study of breast implants and CTDs. 18 These women were individuals who returned a health questionnaire between 1992 and 1995, in response to an invitation to participate in the Women's Health Study, a completed randomized clinical trial (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) testing aspirin and vitamin E in the prevention of cardiovascular disease and cancer. [30] [31] [32] To reduce participant burden, we excluded 46 758 women participating in the Women's Health Study and another clinical trial, the Women's Antioxidant Cardiovascular Study, testing vitamins C and E and beta carotene in the secondary prevention of cardiovascular events, leaving 380 016 eligible women. 33 We then selected all women, not known to be deceased, who reported a history of breast implants on their health questionnaire in 1992-95; these represented the exposed women (n ¼ 10 120). For the unexposed comparison group, we randomly selected five women for each woman reporting breast implants, frequency matched on age (n ¼ 50 592; for a few women, we were unable to obtain five matches). Our rationale for not using the entire cohort of 380 016 women was that the statistical information provided by this 5:1 match would be virtually identical to the full cohort, at substantially lower costs.
Beginning in April 2001, the baseline for the present study, we sent up to three mailings of a brief health questionnaire to the 60 712 women inquiring about socio-demographic factors, health habits and health history, including breast implants and CTDs [rheumatoid arthritis (RA), systemic lupus erythromatosus (SLE), scleroderma, dermatomyositis or polymyositis, Sjogren's syndrome and any other CTD-including mixed]. After excluding those deceased (n ¼ 309), those without valid mailing addresses (n ¼ 5400) and two duplicates, 55 001 remained eligible. A total of 32 439 women responded, an overall response rate of 59.0% (58.8% among the exposed; 59.0% among the unexposed).
Of the 32 439 women, we further excluded the following:
(i) those declining to participate from the beginning (n ¼ 1314); (ii) those missing updated information on breast implant history on the baseline questionnaire, 2001 (breast implant history was initially obtained in 1992-95; n ¼ 46); (iii) those reporting a CTD diagnosis occurring before baseline, or were missing information on a CTD (in order to have a disease-free population at baseline; n ¼ 3412 who were older, heavier, more likely to smoke, less likely to consume alcohol, less likely to use post-menopausal hormones and less active than included women);
(iv) those subsequently declining participation after enrolling (thus providing no follow-up information; n ¼ 3816); and (v) those providing a subsequent diagnosis of a CTD, but we were unable to obtain a date of diagnosis from the participant or their physicians (n ¼ 4).
Our final sample included 23 847 women; 3950 with breast implants and 19 897 without.
Ascertainment of breast implants
On the baseline questionnaire in 2001, we asked whether women had ever had breast implants, and the year of the first procedure. For all women who responded affirmatively, we then sent a detailed questionnaire asking for further information, including a history of up to three breast implant surgeries/ procedures, their date(s), reason(s) for the procedure(s), type of implant(s) and any complications experienced.
Assessment of CTDs
At 1 and 2 years after the return of their baseline questionnaire, women were mailed a detachable postcard. They returned this if they had been diagnosed with myocardial infarction, stroke or transient ischemic attack, cancer, osteoarthritis, fibromyalgia or one of the following CTDs: RA, SLE, scleroderma, dermatomyositis or polymyositis, Sjogren's syndrome and any other CTD-including mixed-and also provided the diagnosis date(s). At the Year 3 and final follow-up, a brief health questionnaire, similar to that at baseline and including questions on CTD diagnosis, was mailed.
Because women returned their questionnaires and postcards in a staggered fashion, we included all final questionnaires up to October 2006. However, 90% of final questionnaires were received by April 2005. We confirmed self-reported CTDs by two methods: using a validated CTD screening questionnaire (CSQ) for symptoms/signs of CTDs ('CSQ confirmed'), which has shown sensitivity of 83-96% for detecting CTDs and specificity of 83-93%, 34 and using medical records ('medical record confirmed'). Women who reported a CTD were first sent the CSQ; those who screened positive on the CSQ were then asked for permission to obtain medical records related to their CTD diagnosis.
Medical records were independently reviewed by two board-certified rheumatologists blinded to breast implant status; the reviewers met to discuss and resolve any discrepancies. CTDs were confirmed according to the American College of Rheumatology (ACR) classification criteria for RA and SLE, 35, 36 preliminary ACR criteria for scleroderma, 37 and published studies of classification criteria for dermatomyositis or polymyositis, Sjogren's syndrome and mixed CTD.
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Statistical analyses
We first compared characteristics of women with and without breast implants. We then used Cox proportional hazards models to estimate the hazard rate ratios of a CTD associated with breast implants. We defined CTDs based on three levels of diagnosis, from the least to the most precise: self-reported CTDs, CTDs that satisfied screening criteria on the CSQ 34 and CTDs confirmed using medical records. Follow-up time was calculated from the date of return of the baseline questionnaire to the latest follow-up questionnaire/postcard for women without a CTD; for women with a CTD, this was calculated to the self-reported date of diagnosis (self-reported and CSQ-confirmed CTD) or date of diagnosis on medical records (medical record confirmed CTD). We first adjusted models for age only, and then also for body mass index (BMI) (continuous variable), smoking (never, past, current) and use of post-menopausal hormones (never, past, current), factors associated with breast implants in the present study, which also have been associated with risk of CTDs. A second multivariate model further adjusted for history of breast cancer.
Because the numbers of several CTD outcomes were small, we conducted sensitivity analyses using propensity score modelling 41 to more efficiently control for potential confounders listed above, as well as additional variables associated with breast implants in the present study that have not been clearly linked to CTD risk. The propensity score model included age, age squared, BMI (<23, 23-24.9, 25-26.9, 27-29.9, 530 kg/m 2 ), smoking (never, past, current), use of post-menopausal hormones (never, past, current), high cholesterol, hypertension (both no, yes), alcohol intake (g/day) and physical activity (<200, 200-599, 600-1499, 51500 kcal/day). A second propensity score model also included history of breast cancer. We then estimated the RRs of CTDs according to the duration of breast implants at baseline (<10, 10 to <20 and 520 years), as well as the type of breast implant (silicone, saline, other and unknown) reported. Table 1 compares the characteristics of women with and without breast implants. Their ages were similar, due to age-matching, but women with implants were leaner, more likely to smoke, to consume more alcohol, to be post-menopausal and using post-menopausal hormones and be more active. They were less likely to have a history of hypertension or high cholesterol. As expected, a history of breast cancer was more common in implanted women. We sent women reporting breast implants a more detailed questionnaire requesting further information regarding their implants, and 3781 women (95.7%) responded. Of these, 2626 women reported having silicone gel implants (69.5%); 1384 women, saline implants (36.6%); and 528 women, both (14.0%). Regarding reasons for having breast implants, 1866 (49.4%) did so to enhance breast size, 1202 (31.8%) for reconstruction following mastectomy, and the remainder cited other reasons (including post-childbirth sagging, asymmetry and cysts). The median duration of implants was 17.1 (25th to 75th percentile, 12.7-23.0) years.
Results
During follow-up [median 3.63 (25th to 75th percentile, 3.54-3.68) years], 113 women (2.9%) from the implanted group reported a diagnosis of any CTD, as did 377 women (1.9%) from the group without breast implants. We mailed a CSQ 34 to all women who reported a CTD diagnosis, and received completed questionnaires from 93 women (82.3%) reporting breast implants, and 287 women (76.1%) without breast implants. In the breast implant group, 77 women (82.8%) screened positive for a potential CTD, whereas 226 women (78.8%) without implants did so. Thus, women with breast implants were more likely to return a CSQ, and also more likely to screen positive for CTDs.
We requested medical records for women who screened positive on the CSQ, and were able to obtain them for 41 (53.3%) and 138 (61.1%) women with and without breast implants, respectively. Medical records confirmed CTD diagnoses in 21 women with breast implants and 74 women without breast implants, representing 51.2% (21 of 41) and 53.6% (74 of 138), respectively, for whom medical records were received, and 27.3% (21 of 77) and 32.7% (74 of 226), respectively, for whom CSQs screened positive. Medical record confirmed CTD represented 18.6% (21 of 113) and 19.6% (74 of 377), respectively, of all self-reported CTD. Thus, a lower proportion of medical records were obtained for women with breast implants compared with non-implanted women, and medical record confirmation of a CTD also tended to be lower in women with breast implants. Table 2 presents the RRs of CTDs, comparing women with and without implants. Of the CTDs, RA was the most commonly reported CTD, numbering 54 and 218 cases, respectively, in the two groups. With increasing strictness of criteria for confirmation, the numbers of confirmed CTD dropped steadily. With self-reported events, there was a 52-60% increase in risk for all CTDs, depending on covariate adjustment. For RA, the RRs ranged from 1.25 to 1.39; for the other individual CTDs, the numbers of cases were small and yielded results with wide CIs. With CSQconfirmed CTD, we continued to observe an increase in risk (73-80%) of all CTDs. For all CTDs confirmed on medical record review, breast implants were associated with a 43% increase in risk (95% CI 0.88-2.33) in age-adjusted analysis, which was further attenuated to a 39% increase (0.82-2.35) after additional adjustments for BMI, smoking and post-menopausal hormone use.
In a secondary analysis accepting a diagnosis of a CTD by the participant's treating physician (i.e. not using strict study criteria adjudicated by study rheumatologists; n ¼ 24 and 82 among women with and without implants, respectively), the corresponding RR of any CTD associated with breast implants was 1.44 (0.89-2.35), similar to the 1.39 for CTDs confirmed using strict study criteria.
Because history of breast cancer was a strong predictor of CTD in the present study, in another secondary analysis, we examined the association of breast implants with CTD, stratifying women by such a history. The results were not notably different, considering the wide CIs, among women without and with a history of breast cancer (data not shown). For example, the multivariate RR for all self-reported CTDs among women without a history of breast cancer was 1.66 (1.28-2.16); among women with a history, 1.30 (0.72-2.34) (in this latter group, there were 34 exposed cases and 22 unexposed cases).
In a sensitivity analysis that used propensity score modelling to more efficiently control for potential confounders as well as additional variables associated We then examined the risk of CTD according to duration of breast implants (Table 3 ). There were no clear trends by duration for CTD confirmed using different degrees of strictness.
Finally, we examined the risk of developing CTD according to type of breast implant (Table 4 ). There were only two cases of CTD confirmed on medical record review among women with saline implants. For CSQ-confirmed CTD, the multivariate-adjusted RR with silicone breast implants was 2.03 (1.50-2.73); for saline implants, 1.45 (0.79-2.66).
Discussion
In this large prospective cohort study, we observed a 60% increase (95% CI 1.28-2.00) in risk of selfreported CTD among women with breast implants, which attenuated to a 39% increase (0.82-2.35) for CTD confirmed using medical records. Although we had hoped that the present study would provide more definitive findings compared with our 1996 retrospective cohort study, 18 methodological limitations inherent to research involving such studies, discussed below, indicate that these results should be viewed with caution. An important lesson learnt is the difficulty of conducting unbiased research related to breast implants and CTDs. Perhaps the most reasonable conclusion that can be drawn from the present results is that there does not appear to be a large increase in risk of a CTD, say 52-fold, associated with breast implants, and with silicone breast implants in particular.
The first methodological concern relates to response rates. The response rate among eligible women was low (59%), but this alone was unlikely to result in bias as the low rate was approximately the same in women with and without implants. When women reported the occurrence of a CTD, they were sent a screening questionnaire for CTDs, the CSQ. 34 Response to this CSQ was differential, higher in women with than without implants (82 vs 76%), which could most likely lead to a bias away from the null. Women screening positive on the CSQ were asked for permission to review their medical records. The receipt of medical records was low, and differential, between implanted and non-implanted women (53 vs 61%), which could most likely lead to a bias towards the null.
A second methodological concern is the ascertainment of CTDs. Although the study was prospective in nature, women with breast implants might be more aware of symptoms and seek medical help, leading to increased reporting of symptoms and diagnosis 
Age-adjusted RR of CTD and a potential bias away from the null. When ascertaining CSQ-confirmed CTD, the proportion confirmed (among women who returned CSQs) was higher among women with than without implants (83 vs 79%), in line with the bias expected. With regard to medical record confirmation, the proportion of CTDs confirmed among those for whom medical records were obtained was low, and lower among women with than without implants (51 vs 54%), also congruent with the expected bias (i.e. CTDs rely in large part on symptoms to establish a diagnosis, and in the clinical setting, a diagnosis may be made with less stringent-fewer-criteria that those used in research [35] [36] [37] [38] [39] [40] 42 ). When calculated as a proportion of all women who reported CTD, the confirmation rate with medical records was very low, but similar among women with and without implants (19 vs 20%) . This very low rate was not unique to the present study; previous studies have reported medical record confirmation of self-reported CTD of between 10 and 24%. 13, 23, 43 The overall rate of RA (the most common CTD) confirmed by medical records in the present study was 53 per 100 000 person-years, lower than the 73-130 per 100 000 comparably aged women per year reported in population-based studies. 44 Incidence rates may be lower because of incomplete response A third methodological concern relates to the rare occurrence of the disease studied, particularly the individual CTDs. The present study represents the second largest prospective cohort study to date, with only the study by Brinton et al. 13 recording a larger number of CTD cases confirmed on medical record review. Even with a cohort of almost 24 000 women, nearly 4000 with implants, followed for 3.6 years, there were few cases of CTD, and particularly scleroderma, the disease most commonly linked to breast implants in case reports and case series. 1 We combined the individual CTDs to obtain larger numbers of events, but the CTDs likely have different etiologies. Additionally, the present study only focused on classical CTDs, and did not seek information on other kinds of autoimmune diseases (e.g. atypical CTD or novel constellation of signs and symptoms in women with silicone breast implants) that also have been postulated to be linked to implants. 1 The present study does possess a number of strengths, including its prospective design which, although not completely removing bias as discussed above, nonetheless can mitigate some bias, compared with case-control studies or retrospective cohort studies. It also used several levels of confirmation of CTD, from self-report to medical record confirmed disease. Although medical records were retrieved from only 53-61% of whom we requested records, this compares well with other studies. For example, in the largest prospective cohort study to date by Brinton et al., 13 medical record retrieval was 35-40%. Finally, the present study collected information on the kinds of implants, allowing differentiation of implants containing silicone, whereas about half of the available studies do not have this information. 26 The results from this study are not congruent with the findings from previous meta-analyses and reviews, which have reported no increase in CTD risk with breast implants, and silicone breast implants in particular. 1, [26] [27] [28] They are more in line with our earlier retrospective cohort study 18 that reported a 24% increase in risk, and a recent large prospective cohort study 13 that reported a 2-fold increase in risk, both of which also possessed many of the same methodological limitations of the present study. The different results across studies likely reflect their different study designs, the small sample sizes of many studies, limited duration of follow-up after breast implants and imprecise ascertainment of breast implants and/or CTD.
In conclusion, this study highlights the complexity of conducting research in the area of breast implants and CTD, particularly with regard to the rarity of the individual diseases of interest, the potential for differential self-reporting of CTD and CTD symptoms among women with and without breast implants, the difficulty of obtaining medical records for participants who reported CTD, and the low and possibly differential confirmation of self-reported disease against medical records. In view of these methodological issues, it is unlikely that future observational epidemiological studies will be able to detect small to moderate increases in risk, whereas randomized clinical trials that can do so are unethical. Perhaps the best advance that we can make is merely to exclude the likelihood of large increases in CTD risk associated with breast implants.
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